Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.43 |
| ▸ | F12 | P00748 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13250121 | 0.95 | PARP1 (0.43) | PARP1TNKS2PARP2P2RX3F12 | |
| SCHEMBL13328851 | 0.92 | F12 (0.43) | PARP1TNKS2PARP2P2RX3F12 | |
| SCHEMBL13250070 | 0.90 | PARP1 (0.44) | PARP1TNKS2PARP2P2RX3F12 | |
| SCHEMBL13250277 | 0.90 | PARP1 (0.45) | PARP1TNKS2PARP2P2RX3F12 | |
| SCHEMBL13249769 | 0.89 | PARP1 (0.48) | PARP1TNKS2PARP2P2RX3F12 | |
| SCHEMBL13250470 | 0.89 | PARP1 (0.46) | PARP1TNKS2PARP2P2RX3F12 | |
| SCHEMBL13249776 | 0.88 | PARP1 (0.47) | PARP1TNKS2PARP2P2RX3F12 | |
| SCHEMBL13250051 | 0.87 | PARP1 (0.47) | PARP1TNKS2PARP2P2RX3F12 | |
| SCHEMBL13250124 | 0.87 | P2RX3 (0.46) | PARP1TNKS2PARP2P2RX3F12 | |
| SCHEMBL13249964 | 0.87 | PARP1 (0.46) | PARP1TNKS2PARP2P2RX3F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| WO-2008130581-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | PARP1 995/4885TNKS2 2045/4885PARP2 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.